Home LiteratureArticle Details
PMID: 15181252 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function.

Journal of molecular neuroscience : MN ·Vol. 23 ·No. 3 ·2004-00-00 ·Pages 235-46

Manelli AM, Stine WB, Van Eldik LJ, LaDu MJ

Abstract

Abnormalities in the processing of amyloid precursor protein to amyloid-beta (Abeta) are causal factors, and the presence of the epsilon4 allele of apolipoprotein E (apoE) is the primary risk factor for Alzheimer's disease (AD). Based, at least in part, on these genetics, the potential structural and functional interactions between these two proteins are the focus of our research. To understand the nature of the physical interactions between apoE and Abeta, we initially utilized gel-shift assays to demonstrate that native apoE2 and E3 (associated with lipid particles) form an SDS-stable complex with Abeta that is more abundant than the apoE4:Abeta complex. We further demonstrated that exogenous apoE3 but not E4 prevents Abeta-induced neurotoxicity by a process that requires apoE receptors. In addition, both exogenous apoE3 and E4 prevent Abeta-induced, glial-mediated inflammation, also via a process that requires apoE receptors. These functional effects all occur at a molar ratio of apoE to Abeta of 1:30. Because the biological activities for both apoE and Abeta are profoundly influenced by their isoform and conformation, respectively, we further investigated the idea that apoE3 and E4 differentially interact with particular aggregation species of Abeta1-42. Our overall hypothesis is that apoE has two general functions in relation to Abeta. First, apoE interacts with oligomeric Abeta via an apoE receptor-mediated process to inhibit neurotoxicity and neuroinflammation (apoE3 > apoE4) a process possibly related to binding and clearance of apoE3:oligomer complexes. Second, apoE facilitates the deposition of Abeta as amyloid (apoE4 > apoE3). We will continue to investigate the effect of apoE isoform and Abeta conformation on the structural and functional interactions between these two proteins in relation to the pathogenesis of AD.

MeSH Terms
Alzheimer Disease/epidemiology,genetics Amyloid beta-Peptides/chemistry,genetics,metabolism Animals Apolipoproteins E/genetics,metabolism Humans Models, Animal Neurofibrils/pathology,physiology Neurons/physiology Peptide Fragments/chemistry,genetics,metabolism Protein Conformation Risk Factors
Chemicals
Amyloid beta-Peptides Apolipoproteins E Peptide Fragments amyloid beta-protein (1-42)
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Manelli Arlene M
Department of Medicine, Division of Geriatrics, Evanston Northwestern Healthcare Research Institute, Evanston, Illinois 60201, USA.
Stine W Blaine
Van Eldik Linda J
LaDu Mary Jo
References (80)
80 references, click to expand
  1. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates.
    J Biol Chem. 1999 Sep 3;274(36):25945-52 PMID: 10464339
  2. Characterization of apolipoprotein J-Alzheimer's A beta interaction.
    J Biol Chem. 1995 Mar 31;270(13):7563-7 PMID: 7706304
  3. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.
    Biochem Biophys Res Commun. 1993 Apr 30;192(2):359-65 PMID: 8484748
  4. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.
    Ann Neurol. 1999 Dec;46(6):860-6 PMID: 10589538
  5. Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures.
    J Biol Chem. 2000 Oct 27;275(43):33974-80 PMID: 10940295
  6. Apolipoprotein E isoform-specific reduction of extracellular amyloid in neuronal cultures.
    Brain Res Mol Brain Res. 1999 May 7;68(1-2):181-5 PMID: 10320795
  7. Apolipoprotein E4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease.
    J Neurosci. 2002 Dec 1;22(23):10083-7 PMID: 12451108
  8. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease.
    J Biol Chem. 1996 Aug 23;271(34):20631-5 PMID: 8702810
  9. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1977-81 PMID: 8446617
  10. An honorable compromise regarding amyloid in Alzheimer disease.
    Ann Neurol. 2001 May;49(5):684 PMID: 11357963
  11. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein.
    Microsc Res Tech. 2000 Aug 15;50(4):316-24 PMID: 10936886
  12. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.
    Proc Natl Acad Sci U S A. 1998 May 26;95(11):6448-53 PMID: 9600986
  13. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.
    Science. 2002 Jul 19;297(5580):353-6 PMID: 12130773
  14. Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro.
    Am J Pathol. 1994 Nov;145(5):1030-5 PMID: 7977635
  15. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid.
    J Biol Chem. 1995 Apr 21;270(16):9039-42 PMID: 7721816
  16. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.
    Nat Genet. 1997 Nov;17(3):263-4 PMID: 9354781
  17. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.
    Am J Pathol. 1999 Sep;155(3):853-62 PMID: 10487842
  18. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse.
    J Neurosci. 1997 Sep 15;17(18):7053-9 PMID: 9278541
  19. Protofibrils, the unifying toxic molecule of neurodegenerative disorders?
    Nat Neurosci. 2001 Sep;4(9):859-60 PMID: 11528409
  20. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease.
    Biochemistry. 1997 Aug 26;36(34):10571-80 PMID: 9265639
  21. Alzheimer's disease and apolipoprotein E-4 allele in an Amish population.
    Ann Neurol. 1996 Jun;39(6):700-4 PMID: 8651641
  22. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides.
    Nat Genet. 1996 Sep;14(1):55-61 PMID: 8782820
  23. Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations.
    J Neurochem. 1996 Jun;66(6):2410-8 PMID: 8632164
  24. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress.
    Exp Neurol. 1995 Nov;136(1):22-31 PMID: 7589331
  25. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability.
    J Biol Chem. 2002 Aug 30;277(35):32046-53 PMID: 12058030
  26. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region.
    Hum Mol Genet. 1994 Apr;3(4):569-74 PMID: 8069300
  27. Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity.
    Lancet. 1995 Dec 9;346(8989):1524-8 PMID: 7491048
  28. Apolipoprotein E affects the amount, form, and anatomical distribution of amyloid beta-peptide deposition in homozygous APP(V717F) transgenic mice.
    Acta Neuropathol. 2000 Nov;100(5):451-8 PMID: 11045665
  29. Alzheimer amyloid-beta peptide forms denaturant-resistant complex with type epsilon 3 but not type epsilon 4 isoform of native apolipoprotein E.
    Mol Med. 1996 Mar;2(2):175-80 PMID: 8726460
  30. Characterization of the binding of amyloid-beta peptide to cell culture-derived native apolipoprotein E2, E3, and E4 isoforms and to isoforms from human plasma.
    J Neurochem. 1997 Feb;68(2):721-5 PMID: 9003062
  31. Apolipoprotein E suppresses glial cell secretion of TNF alpha.
    J Neuroimmunol. 1997 Jun;76(1-2):70-4 PMID: 9184634
  32. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.
    Biochem J. 1993 Jul 1;293 ( Pt 1):27-30 PMID: 8328966
  33. SP-40,40 is a constituent of Alzheimer's amyloid.
    Acta Neuropathol. 1992;83(3):260-4 PMID: 1373021
  34. Alzheimer A beta neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A beta-related peptides.
    Neurobiol Aging. 1996 Sep-Oct;17(5):773-80 PMID: 8892351
  35. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease.
    Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2892-7 PMID: 10694577
  36. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis.
    J Biol Chem. 2003 Mar 28;278(13):11612-22 PMID: 12499373
  37. Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro.
    J Neurosci Res. 1999 Aug 15;57(4):504-20 PMID: 10440900
  38. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation.
    Nat Med. 1999 May;5(5):560-4 PMID: 10229234
  39. Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions.
    Neuron. 1993 Oct;11(4):575-80 PMID: 8398148
  40. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease.
    Brain Res. 1991 Feb 8;541(1):163-6 PMID: 2029618
  41. Attenuation of the neurotoxic effect of A beta amyloid peptide by apolipoprotein E.
    Biochem Biophys Res Commun. 1994 Feb 28;199(1):163-70 PMID: 8123007
  42. ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide.
    J Neurochem. 2001 Jan;76(1):117-27 PMID: 11145984
  43. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.
    J Neurosci. 1999 Oct 15;19(20):8876-84 PMID: 10516307
  44. Association of human, rat, and rabbit apolipoprotein E with beta-amyloid.
    J Neurosci Res. 1997 Jul 1;49(1):9-18 PMID: 9211985
  45. Cerebrovascular smooth muscle cells internalize Alzheimer amyloid beta protein via a lipoprotein pathway: implications for cerebral amyloid angiopathy.
    Lab Invest. 1997 Aug;77(2):157-66 PMID: 9274858
  46. The Sixth International Conference on Alzheimer's disease, Amsterdam, The Netherlands, July 1998. The amyloid cascade hypothesis debate: emerging consensus on the role of A beta and amyloid in Alzheimer's disease.
    Amyloid. 1998 Dec;5(4):301-4 PMID: 10036589
  47. Isoform-specific effect of apolipoprotein E on cell survival and beta-amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures.
    J Neurosci. 1998 Jan 1;18(1):195-204 PMID: 9412500
  48. Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis.
    J Lipid Res. 1999 Mar;40(3):447-55 PMID: 10064733
  49. Alzheimer's disease: genes, proteins, and therapy.
    Physiol Rev. 2001 Apr;81(2):741-66 PMID: 11274343
  50. Endogenous apolipoprotein E suppresses LPS-stimulated microglial nitric oxide production.
    Neuroreport. 1998 Mar 9;9(4):615-8 PMID: 9559926
  51. Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease.
    Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3342-4 PMID: 10097040
  52. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases.
    Lancet. 1993 Sep 18;342(8873):710-1 PMID: 8103823
  53. Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum?
    Trends Neurosci. 2001 Apr;24(4):219-24 PMID: 11250006
  54. The apolipoprotein E/CI/CII gene cluster and late-onset Alzheimer disease.
    Am J Hum Genet. 1994 Apr;54(4):631-42 PMID: 8128960
  55. Isoform-specific modulation by apolipoprotein E of the activities of secreted beta-amyloid precursor protein.
    J Neurochem. 1997 Jul;69(1):60-7 PMID: 9202294
  56. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides.
    Biochem J. 2000 Jun 1;348 Pt 2:359-65 PMID: 10816430
  57. Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease.
    Ann Neurol. 1995 May;37(5):596-604 PMID: 7755354
  58. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease.
    Nat Genet. 1994 Jun;7(2):180-4 PMID: 7920638
  59. Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response.
    J Neuroimmunol. 2001 Mar 1;114(1-2):107-13 PMID: 11240021
  60. Apolipoprotein E attenuates beta-amyloid-induced astrocyte activation.
    J Neurochem. 1998 Oct;71(4):1626-34 PMID: 9751196
  61. Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis.
    J Biol Chem. 1997 Jul 18;272(29):17972-80 PMID: 9218423
  62. Apolipoprotein E promotes the binding and uptake of beta-amyloid into Chinese hamster ovary cells in an isoform-specific manner.
    Neuroscience. 1999;90(4):1217-26 PMID: 10338292
  63. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E.
    Nature. 1997 Aug 28;388(6645):878-81 PMID: 9278049
  64. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments.
    Nature. 1994 Nov 3;372(6501):92-4 PMID: 7969426
  65. Apolipoprotein E epsilon 2 allele promotes longevity and protects patients with Down's syndrome from dementia.
    Neuroreport. 1994 Dec 20;5(18):2583-5 PMID: 7696609
  66. Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese.
    Neurology. 1996 Jan;46(1):146-9 PMID: 8559364
  67. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.
    Science. 1993 Aug 13;261(5123):921-3 PMID: 8346443
  68. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.
    Nature. 2002 Apr 4;416(6880):535-9 PMID: 11932745
  69. Apolipoprotein E and apolipoprotein E receptors modulate A beta-induced glial neuroinflammatory responses.
    Neurochem Int. 2001 Nov-Dec;39(5-6):427-34 PMID: 11578778
  70. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.
    JAMA. 2000 Mar 22-29;283(12):1571-7 PMID: 10735393
  71. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease.
    Proc Natl Acad Sci U S A. 1995 Jan 31;92(3):763-7 PMID: 7846048
  72. Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer's disease.
    Nat Genet. 1994 May;7(1):74-8 PMID: 8075646
  73. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform apoE4 associates more efficiently than apoE3.
    J Clin Invest. 1994 Aug;94(2):860-9 PMID: 8040342
  74. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease.
    J Clin Invest. 1999 Mar;103(6):R15-R21 PMID: 10079115
  75. Oligomerizaiton and fibril asssembly of the amyloid-beta protein.
    Biochim Biophys Acta. 2000 Jul 26;1502(1):31-43 PMID: 10899429
  76. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid.
    Neurosci Lett. 1992 Feb 3;135(2):235-8 PMID: 1625800
  77. Apolipoprotein E: risk factor for Alzheimer disease.
    Am J Hum Genet. 1994 Apr;54(4):643-9 PMID: 8128961
  78. Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains.
    J Biol Chem. 1996 Feb 23;271(8):4077-81 PMID: 8626743
  79. Apolipoprotein E gene expression in astrocytes: developmental pattern and regulation.
    Neuroreport. 1995 Dec 29;7(1):205-8 PMID: 8742452
  80. Isoform-specific binding of apolipoprotein E to beta-amyloid.
    J Biol Chem. 1994 Sep 23;269(38):23403-6 PMID: 8089103
Article Info
Journal
Journal of molecular neuroscience : MN
Abbr.
J Mol Neurosci
ISSN
0895-8696
Published
2004-00-00
Pages
235-46
Language
English
Region
United States
NLM ID
9002991
Subset
IM
Grants
NIA NIH HHS · AG13939 · United States
NIA NIH HHS · AG19121 · United States
NIA NIH HHS · AG21184 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com